Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 3/20 | 0.48 |
| ▸ | DHODH | Q02127 | 3/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.39 |
| ▸ | GNRHR | P30968 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.38 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7652922 | 0.88 | CTSK (0.50) | CTSKADORA3ADORA2AADORA1 | |
| SCHEMBL7656086 | 0.88 | CTSK (0.45) | CTSKADORA3ADORA2AADORA1ROCK2 | |
| SCHEMBL7649212 | 0.87 | CTSK (0.47) | CTSKGNRHRMAPTRXFP1ADORA2A | |
| SCHEMBL7652889 | 0.85 | CTSK (0.45) | CTSKADORA3GNRHRMAPTADORA2A | |
| Dimethylamine SCHEMBL7652490 | 0.81 | DHODH (0.52) | CTSKDHODHADORA3MAPTTHRB | |
| SCHEMBL7652516 | 0.81 | CTSK (0.46) | CTSK | |
| SCHEMBL7650966 | 0.80 | ADORA3 (0.45) | CTSKDHODHADORA3MAPTADORA2A | |
| SCHEMBL7653733 | 0.80 | NPC1 (0.40) | CTSKADORA3GNRHRMAPT | |
| SCHEMBL7679154 | 0.78 | ALDH1A1 (0.46) | CTSKADORA3MAPTROCK2 | |
| SCHEMBL7655384 | 0.77 | HPGD (0.43) | ADORA3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6492407-B2 | NEUROPROTECTIVE ACTIVITY | BOEHRINGER IMGELHEIM PHARMA KG (DE) | 2002-12-10 | — | — | US | claimed |
| US-20020045651-A1 | Pharmaceutical compositions containing triazolones and methods of treating neurodegenerative disease using triazolones | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-04-18 | — | — | US | claimed |
| US-6492407-B2 | NEUROPROTECTIVE ACTIVITY | BOEHRINGER IMGELHEIM PHARMA KG (DE) | 2002-12-10 | — | — | US | disclosed |
| US-20020045651-A1 | Pharmaceutical compositions containing triazolones and methods of treating neurodegenerative disease using triazolones | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045651-A1 | Pharmaceutical compositions containing triazolones and methods of treating neurodegenerative disease using triazolones | PARK7, IAPP, HIF1AN | CTSK 1300/4885DHODH 3668/4885ADORA3 1892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.